Intas Pharma Inks Agreement with mAbxience for Etanercept Biosimilar

Further, Intas will leverage mAbxience’s strong sales, marketing capabilities and experience in commercialising new biosimilars. While, mAbxience will be responsible for the development, manufacturing, and supply of the Etanercept biosimilar from its state-of-the-art, Good Manufacturing Practices (GMP) approved facilities.

Ahmedabad-based leading multinational pharmaceutical company, Intas Pharmaceuticals Ltd has entered into an exclusive licencing agreement with Spanish’s mAbxience for Etanercept Biosimilar.

According to the license agreement, Intas receives exclusive rights to commercialise Etanercept biosimilars, through its affiliates, for the treatment of various autoimmune diseases, in more than 150 countries across the globe, including Europe and the United States of America.

Further, Intas will leverage mAbxience’s strong sales, marketing capabilities and experience in commercialising new biosimilars. While, mAbxience will be responsible for the development, manufacturing, and supply of the Etanercept biosimilar from its state-of-the-art, Good Manufacturing Practices (GMP) approved facilities.

However, the financial terms of the agreement are yet to be disclosed. This global collaboration seeks to enable innovative and affordable treatment options for autoimmune diseases.

With this new partnership, Intas and mAbxience are poised to make a lasting impact on the lives of millions affected by autoimmune diseases while also strengthening Intas' leadership in the global biosimilar landscape.

On the collaboration, Binish Chudgar, VC Instas, saidz, "Partnering up with mAbxience, who are known for their dedication to quality and innovation, aligns perfectly with our vision. This partnership enables us to achieve our goal of providing high-quality treatments to patients worldwide. Together, we aim to revolutionise the landscape of autoimmune disease treatment."

Etanercept is a dimeric fusion protein with tumor necrosis factor (TNF) blocking action that was approved for use over 20 years ago, offering patients a valuable therapeutic option for treating various autoimmune diseases. According to IQVIA, global sales of Etanercept for 12 months, ending June 2023, were $ 11 billion.

Founded in 1977 by Hasmukh Chudgar, Intas Pharma aims to provide high-quality medicines at affordable prices to patients with various diseases such as CNS, Cardio, Diabeto, Gastro, Urology, and Oncology. It also focuses on developing and manufacturing biosimilar products based on recombinant DNA and monoclonal antibodies.

"Expanding our global reach has always been at the core of mAbxience's vision. Collaborating with Intas allows us to tap into new markets and bring our cutting-edge biosimilar candidate to countless patients battling autoimmune diseases. It reinforces our dedication to leading the way in the biosimilar industry," said Jurgen Van Broeck, global commercial director, mAbxience.

While mAbxience, on the other hand, is a global biotech company, founded in 2010 by Dr Hugo Sigman. The company aims to provide end-to-end services in the B2B biopharmaceutical space, ensuring everything it delivers worldwide is world-class. It specialises in biologics, especially biosimilars, and has a core R&D competency.

Earlier, Abbott partnered with mAbxeinece to commercialise biosimilars in emerging markets. The collaboration further aims to make these advanced medicines more accessible and affordable in these emerging countries that lack advanced treatments by leveraging Abbott's broad in-country footprint.